Compare JetBlue Airways Corporation (JBLU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Repligen Corporation Common Stock — how do they compare? JetBlue Airways Corporation trades at $3.02 (market cap $1.13B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 10× JetBlue Airways Corporation's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Repligen Corporation Common Stock for 0 Days on average.
| JBLU | RGEN | |
|---|---|---|
Market Cap | $1.13B | $11.31B |
Volume | 40,474,891 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $6.46 | $194.57 |
52-Week Low | $3.01 | $102.87 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.50B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.35, down 7.46% today, reflecting persistent bearish sentiment amid negative earnings and high debt. The technical outlook is bearish with key support at $3, while fundamentals show revenue near $9.1B but net losses widening, with a negative ROE of -44.36%. Recent news includes route expansion in Colombia but also capacity cuts and elevated fuel costs pressuring margins.
The stock faces significant headwinds from consecutive quarterly losses and rising leverage, yet analyst consensus suggests a $5.89 price target implies potential upside if cost controls improve. Key risks include volatile fuel prices, competitive pressures, and execution of the JetForward strategy amidst a challenging macroeconomic backdrop for airlines.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
